Summit Therapeutics
OrganizationHeard in 2 episodes across 2 shows since Sep 2026
Summit Therapeutics Inc. is a publicly traded biotechnology company focused on developing and commercializing innovative medicines for serious diseases, particularly cancer. Its lead program is ivonescimab, an investigational PD-1/VEGF bispecific antibody licensed from Akeso for development and commercialization in specified territories.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 1 |
| Oct 2026 | 1 |
Email alert
Email me when Summit Therapeutics comes up on a podcast
One email a week at most, with the new episodes that mention Summit Therapeutics. Free, no account needed, unsubscribe in one click.
What experts have said about Summit Therapeutics
3 statements · 2 positive · 1 negative
Summit Therapeutics shares rose 19%.
“Summit Therapeutics, another big gainer, this one up 19% under ticker SMMT.”
Open the episode · Navitas Soars; AstraZeneca Invests $2 Billion in Summit; FICO DropsListen at 1:37
Summit Therapeutics shares rose 19%.
“Summit Therapeutics, another big gainer, this one up 19% under ticker SMMT.”
Open the episode · Navitas Soars; AstraZeneca Invests $2 Billion in Summit; FICO DropsListen at 1:37
Summit Therapeutics shares were 40% below their April peak.
“They were down 40% from their April peak”
Open the episode · Navitas Soars; AstraZeneca Invests $2 Billion in Summit; FICO DropsListen at 2:11
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
2 episodes featuring Summit Therapeutics, newest first
